Honeywell Aerospace Inc. Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? Honeywell Aerospace Inc. Common Stock trades at $155.9 (market cap $50.14B), while Zimmer Biomet Holdings Inc trades at $92.24 (market cap $17.56B). The key difference: Honeywell Aerospace Inc. Common Stock is far larger — about 2.9× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.04% dividend while Honeywell Aerospace Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell Aerospace Inc. Common Stock for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HONA | ZBH | |
|---|---|---|
Market Cap | $50.14B | $17.56B |
Volume | 1,433,364 | 2,298,426 |
Sector | Industrials | Health |
52-Week High | $269.95 | $103.98 |
52-Week Low | $151.58 | $79.58 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $64.96B | $24.63B |
Dividend Yield | — | 1.04% |
Signals from Pluang's Aura AI — not financial advice
HONA trades at $158.18, up 0.58% today, with neutral technical indicators showing support at $156 and resistance at $160. The company reported Q2 2026 EPS of $1.87, missing expectations of $2.07, while revenue grew to $17.40B in 2025. Analyst consensus remains mixed with a $211.25 price target, but multiple class action lawsuits filed in October 2026 create significant legal overhang.
HONA faces near-term headwinds from earnings miss and legal challenges, though strong cash flow generation and analyst price targets suggest long-term potential. Investors should weigh the 42.9% buy rating against litigation risks and declining profit margins projected for 2026.
Zimmer Biomet (ZBH) trades at $91.77, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady at $8.23B for 2025, though net income margins have moderated from 13.84% in 2023 to 8.56% in 2025. The company maintains strong profitability with a 69.87% gross margin and recently announced a $0.24 quarterly dividend.
ZBH presents a mixed outlook with positive earnings momentum and analyst consensus price target of $103.11 offering 12% upside potential. However, rising debt levels and competitive pressures in medical technology pose risks. Institutional ownership trends show continued interest, with State Street increasing its position by 0.6% in Q3 2026. The stock's valuation at 22.35 P/E appears reasonable given the company's market leadership position.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Honeywell Aerospace Inc. is an aerospace and defense technology company, spun off from Honeywell in June 2026, that designs and supplies avionics, propulsion components (including auxiliary power units and engines), and connectivity systems for commercial, defense, and space aircraft.
Read more on HONA →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →